Our FibroScan family of products
FibroScan is a pain-free, non-invasive examination of the liver, providing physicians with both liver stiffness and liver fat scores in a single 10-minute procedure. Our FibroScan family of products all come equipped to offer you the same capabilities and examination experience, allowing you the flexibility to choose the size and portability options that suit your needs best.
Unprecedented Mobility for Liver Assessment Efficiency
The FibroScan mini+ is our most portable system, weighing in just over 10lbs, our mini+ is the smallest addition to the FibroScan family of products for access to those who need it most.
Learn more
Innovation in Liver Disease Management
With its optional roll stand, big 15” touchscreen display, durable yet ergonomic design, the FibroScan Compact is a perfect liver assessment solution for any point-of-care setting.
Learn more
FDA Cleared
FibroScan is the first and only point of care device specifically developed and FDA-Cleared as an aid to the diagnosis and monitoring of adult patients with liver disease. The Shear wave speed stiffness generated by the FibroScan examination may be used as an aid to clinical management of pediatric patients with liver disease.
Learn more about FDA clearance
Deployed at Beth Israel
"FibroScan is the most effective and best screening test for the diagnosis of chronic liver disease"
Nezam Afdhal, MD
Beth Israel Deaconess Medical Center
See how FibroScan is helping BIDMC
Current media
Noninvasive Tests Cost-Effectively Identify Patients at Risk for Liver Disease
Primary care physicians and specialists face the challenges of addressing the epidemic of liver disease, including nonalcoholic fatty liver disease (NAFLD)--a silent and potentially reversible condition—and its subtype nonalcoholic steatohepatitis…
Read More
Echosens Featured in OncologyTube
Scott Howell, DO, MPH & TM, CPE, Advisor to Echosens, was featured in OncologyTube interview: “Underlying Nonalcoholic Fatty Liver Disease is a Significant Factor for Breast Cancer Recurrence After Curative…
Read More
Comprehensive Economical Analysis Shows Screening Diabetic Patients for NAFLD is Cost Effective in the United States
The prevalence of non-alcoholic fatty liver disease (NAFLD) has reached epidemic levels. The most common liver disease, with a worldwide prevalence of 25%, NAFLD and its subtype, nonalcoholic steatohepatitis (NASH),…
Read More
Contact a representative
In North America there are over 1200+ FibroScan systems in operation & we’re growing!
Speak to a Representative
